| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | STX1A |
| Uniprot No | Q16623 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-265aa |
| 氨基酸序列 | MKDRTQELRTAKDSDDDDDVAVTVDRDRFMDEFFEQVEEIRGFIDKIAEN VEEVKRKHSAILASPNPDEKTKEELEELMSDIKKTANKVRSKLKSIEQSI EQEEGLNRSSADLRIRKTQHSTLSRKFVEVMSEYNATQSDYRERCKGRIQ RQLEITGRTTTSEELEDMLESGNPAIFASGIIMDSSISKQALSEIETRHS EIIKLENSIRELHDMFMDMAMLVESQGEMIDRIEYNVEHAVDYVERAVSD TKKAVKYQSKARRKK |
| 预测分子量 | 31 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于STX1A重组蛋白的3篇参考文献示例(内容基于研究领域常见方向，非真实文献)：
1. **"Expression and Purification of Recombinant STX1A for Structural Analysis"**
- 作者：Chen, L. et al.
- 摘要：研究通过大肠杆菌系统表达并纯化重组STX1A蛋白，优化了表达条件以提高溶解度，利用X射线晶体学解析其结构，揭示了其与SNARE复合体结合的分子机制。
2. **"STX1A Recombinant Protein Facilitates Synaptic Vesicle Fusion In Vitro"**
- 作者：Morimoto, T. & Yamaguchi, S.
- 摘要：通过体外重构实验，证明重组STX1A蛋白与VAMP2/SNAP-25形成功能性SNARE复合体，直接驱动囊泡融合，并定量分析了其动力学参数。
3. **"Role of Recombinant STX1A in Neurodegenerative Disease Models"**
- 作者：Kumar, R. et al.
- 摘要：在帕金森病细胞模型中，重组STX1A蛋白被用于恢复突触囊泡运输功能，结果表明其过表达可部分挽救多巴胺能神经元的递质释放缺陷。
(注：以上文献为示例性内容，实际引用请查询PubMed、Google Scholar等数据库获取真实文献。)
**Background of STX1A Recombinant Protein**
Syntaxin-1A (STX1A) is a key protein involved in intracellular membrane trafficking and neurotransmitter release, primarily functioning within the SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) complex. It plays a critical role in mediating vesicle docking and fusion at neuronal presynaptic terminals, enabling the release of neurotransmitters such as acetylcholine, dopamine, and glutamate. STX1A is characterized by its conserved SNARE domain, which facilitates interactions with partner proteins like SNAP-25 and synaptobrevin (VAMP), forming the core machinery for membrane fusion.
The recombinant STX1A protein is engineered through molecular cloning techniques, often expressed in *E. coli* or mammalian cell systems to ensure proper folding and post-translational modifications. Purification typically involves affinity chromatography, yielding high-purity, bioactive protein for research applications. Recombinant STX1A is widely utilized to study synaptic transmission mechanisms, neurodevelopmental disorders, and neurodegenerative diseases (e.g., Alzheimer’s, Parkinson’s). It also serves as a tool for investigating SNARE complex assembly/disassembly dynamics and screening therapeutic agents targeting exocytosis pathways.
Dysregulation of STX1A has been linked to epilepsy, schizophrenia, and autism spectrum disorders, underscoring its relevance in neuropathology. Its recombinant form enables precise in vitro and in vivo studies, advancing understanding of synaptic plasticity and potential treatments for neurological conditions.
×
